Latest Capital Raising News

Elixir Energy has expanded its footprint in Queensland's Taroom Trough through a farmin deal with Santos, boosting its contingent gas resources by 68% and launching a $9 million equity raise to fund upcoming exploration activities.

Amaero has completed a A$22 million institutional placement, concluding nearly A$100 million raised since 2022 and positioning itself for commercialisation in FY2026 with a robust balance sheet.

Resouro Strategic Metals Inc. posted a $5.28 million net loss for the nine months ended December 31, 2024, reflecting increased exploration and administrative expenses as it advances its Tiros Titanium and Rare Earth Elements Project. The company bolstered its balance sheet with a successful ASX dual listing and private placements but faces ongoing challenges to sustain operations.

Mantle Minerals Limited has announced a significant 10-for-1 consolidation of its ordinary shares and performance rights, set to reshape its capital structure by March 2025. This move aims to streamline the company’s share register ahead of renewed market activity.

Lodestar Minerals has increased its capital raising placement by $22,500, bringing the total to $542,500, subject to shareholder approval at an upcoming meeting.

Alterity Therapeutics has raised A$40 million through a two-tranche placement to advance its lead compound ATH434 for neurodegenerative diseases, including Multiple System Atrophy and Parkinson's disease.

Inventis Limited updates its operational review with corrected financials, securing major orders and pursuing significant capital raises to fuel international expansion.

Polymetals has raised $35 million through a share placement to fund the restart of its Endeavor silver and zinc mine and accelerate exploration efforts, positioning the company for production in Q2 2025.

Advance Metals has secured $1.52 million to fund diamond drilling at its Myrtleford Project in Victoria and confirmatory drilling at its Yoquivo Silver Project in Mexico, with drilling commencing immediately.

Wellnex Life Limited has announced a non-renounceable entitlement offer to raise approximately $22.1 million at $0.65 per share, supporting its planned AIM listing and strategic growth initiatives.

Arovella Therapeutics has requested a voluntary suspension of its ASX-listed securities pending a material announcement on a capital raising, expected by 17 February 2025.

Wellnex Life Limited has initiated a $22.1 million entitlement offer priced at $0.65 per share, coinciding with its proposed dual listing on the London Stock Exchange's AIM market, driven by strong UK institutional interest.